← All trials
NCT05739474
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 19, 2022
- Primary completion
- Jun 30, 2023
- Completion date
- Dec 30, 2023
- First posted
- Feb 22, 2023
- Last posted
- Aug 30, 2023
- Enrollment
- 948
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.